a受体阻滞剂对肾盂压力变化的影响
|
摘要
目的:观察a受体阻滞剂对梗阻后兔肾盂压力的影响。
方法:本实验将48只家兔随机分组,人为造成家兔输尿管梗阻,实验组(A组)给予a受体阻滞剂,对照组(B组)予以生理盐水,检测各组服药前后的肾盂压力改变。
结果:对照组肾盂压力从8.60±1.77cmH_2O升高到17.92±2.58cmH_2O,梗阻组肾盂压力从8.42±1.50cmH_2O升高到17.92±2.56cmH_2O,两组自身前后比较具有统计学意义(P＜0.05)。梗阻组肾盂压力从17.92±2.56cmH_2O下降到14.56±3.30cmH_2O,差异有显著性(P＜0.01)。
结论:1.输尿管梗阻后兔肾盂压力明显上升。2.a受体阻滞剂可减轻输尿管梗阻后兔肾盂的压力,可能与a受体阻滞剂松弛输尿管下段、膀胱三角区及膀胱颈平滑肌有关。
Objiective:To observe the impact of a-adrenoreceptor blocker of rabbit renal pelvis pressure of obstruction.
Methods:Carry 48 rabbits through experiment with randomized, make the urinary system block of rabbits' in man-made,the experimental group(A group) feed through Terazosin Hydrochloride Tablets,and the control group(B group) feed through saline.Detect the changes of the renal pelvis pressure of each group rabbits before and after medication.
Results:Control group,renal pelvis pressure increased from 8.60±1.77cmH2O to 17.92±2.58cmH2O,while obstruction group pelvis pressure increased from 8.42±1.50cmH2o to 17.92±2.56cmH2O,Comparison of the two groups before and after their were statistical significance(P＜0.05 ).The obstruction group pelvis pressure dropped from 17.92±2.56cmH2O to 14.56±3.30cmH2O,There was a significant difference(P＜0.01).
Conclutions:1 Ureteral obstruction significantly increased the pressure of the rabbit renal pelvis.2.A-adrenoreceptor blocker can reduce the pressure of the rabbit renal pelvis on rabbit after ureteral obstruction,which may be associated with a lower relaxation ureter and bladder trigone and bladder neck smooth muscle-related under the effection of a-adrenoreceptor blocker.
方法:本实验将48只家兔随机分组,人为造成家兔输尿管梗阻,实验组(A组)给予a受体阻滞剂,对照组(B组)予以生理盐水,检测各组服药前后的肾盂压力改变。
结果:对照组肾盂压力从8.60±1.77cmH_2O升高到17.92±2.58cmH_2O,梗阻组肾盂压力从8.42±1.50cmH_2O升高到17.92±2.56cmH_2O,两组自身前后比较具有统计学意义(P＜0.05)。梗阻组肾盂压力从17.92±2.56cmH_2O下降到14.56±3.30cmH_2O,差异有显著性(P＜0.01)。
结论:1.输尿管梗阻后兔肾盂压力明显上升。2.a受体阻滞剂可减轻输尿管梗阻后兔肾盂的压力,可能与a受体阻滞剂松弛输尿管下段、膀胱三角区及膀胱颈平滑肌有关。
Objiective:To observe the impact of a-adrenoreceptor blocker of rabbit renal pelvis pressure of obstruction.
Methods:Carry 48 rabbits through experiment with randomized, make the urinary system block of rabbits' in man-made,the experimental group(A group) feed through Terazosin Hydrochloride Tablets,and the control group(B group) feed through saline.Detect the changes of the renal pelvis pressure of each group rabbits before and after medication.
Results:Control group,renal pelvis pressure increased from 8.60±1.77cmH2O to 17.92±2.58cmH2O,while obstruction group pelvis pressure increased from 8.42±1.50cmH2o to 17.92±2.56cmH2O,Comparison of the two groups before and after their were statistical significance(P＜0.05 ).The obstruction group pelvis pressure dropped from 17.92±2.56cmH2O to 14.56±3.30cmH2O,There was a significant difference(P＜0.01).
Conclutions:1 Ureteral obstruction significantly increased the pressure of the rabbit renal pelvis.2.A-adrenoreceptor blocker can reduce the pressure of the rabbit renal pelvis on rabbit after ureteral obstruction,which may be associated with a lower relaxation ureter and bladder trigone and bladder neck smooth muscle-related under the effection of a-adrenoreceptor blocker.
引文
[1]裴顺祥,孙颖浩,瞿创予,廖国强。尿道压力分布图对O[-受体阻滞剂治疗BPH效果的预测。临床泌尿外科杂志,2000,07(15)
[2]Cooper JT,stack GM.Intensive Medical management of ureteral calculi.Urology,2000,56(4):575-578
[3]Sigala S,Dellabella M,Milanese G;et al.Evidence for the presence of alphal adrenoceptor subtypes in the human ureter.Neurourol Urodyn,2005,24(2):142-148.
[4]孙西钊,叶章群.。肾绞痛诊断和治疗新概念.临床泌尿外科杂志,2007,10(5):321-323.
[5]Borghi L,Meschi T,Amato F,et al.Nifedipine and methylprednisolone in facilitating ureteral stone passage:a randomized,doubleblind,placebo-controlled study.J Urol,1994,152(4):1095--1098.
[6]Parsons JK,Hergan LA,Sakamoto K,et al.Efficacy of alpha-Blockers for the Treatment ofUreteral Stones.J Urol,2007,177(3):983--987.
[7]李涛,何延瑜,陈圣,等.特拉唑嗪联合硝苯地平治疗输尿管末端结石的随机对照临床研究.中华泌尿外科杂志,2007,28(2):111-114.
[8]叶章群,尿石症诊断治疗指南。那彦群主编,中国泌尿外科疾病诊断治疗指南。北京:人民卫生出版社。
[9]Cervenakov I,Fillo J,Mardiak J,et al.Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker-Tamsulosin.Int Urol Nephrol,2002,34(1):25-29.
[10]王风,曹清丽,张瑜,等.盐酸坦索罗辛治疗输尿管远段小结石的临床研究.中国医师进修杂志:外科版,2006,29(10):52-53.
[11]Rocco D.Riccardo A.Ciro E Stent positioning after ureteroscopy for urinary calcail:The question is still open 2004(3)
[12]刘福泉 童高寅α受体阻滞剂在输尿管下段结石临床应用,浙江临床医学2008,10(10)9
[13]Gravina GI.Costa AM.Ronchi P Tamsulosin treatment increases clinical success rate of single extra corporeal shock wave lithotripsy of renal stones 20050
[14]Resim S.Ekerbicer H K.Cifit A Role of Tamsulosin in treatment of patients with steinstrasse developing after extracorporeal shock wave lithotripsy 2005(5)
[15]丁森泰,吕家驹,叶章群.Cc受体阻滞剂在输尿管下段结石治疗中的研究.临床泌尿外科杂志,2007,22(5):394-396.
[16]Dellabella M,Milanese G,Muzzonigre GRandomized trial of the efficacy of tamsulosin,nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi.J Urol,2005,174(1):167--172.
[17]2007Teichman JM.Clinical practice.Acute renal colic from ureteral calculus.NEngl J Med,2004,350(7):684--693.
[1]Akasaka T,Funaki H,Hirano S,Ohinata M,Fujishima M,Kudou T,Suzuki A,Iinuma M.Department of Urology,Akasaka Hospital..Hinyokika Kiyo.2003Apr;49(4):189-93.
[2]汤平,谢克基,α1-肾上腺素能受体阻滞剂与前列腺细胞凋亡[J].广东医学L,2002 Vo1.23 No.7 P.765-767
[3]Kyprianou N.Division of Urology,Department of Surgery,University of Kentucky Medical Center,Lexington,USA.J Urol.2003 Apr;169(4):1520-5.
[4].Wilt T J,Mac Donald R,Rutks I.General Internal Medicine(111-0),Minneapolis VA/VISN 23 Center for Chronic Disease Outcomes Research,One Veterans Drive,Minneapolis,Minnesota 55417,USA.Tim.Wilt@rned.va.gov Cochrane Database Syst Rev.2003;(1):CD002081
[5]Thiyagarajan M.Department of Pharmacology and Toxicology,National Institute of Pharmaceutical Education and Research,SAS Nagar(Mohali),India.m-t-rajan@hotmail.com Pharmacology.2002 Jul;65(3):119-28.
[6]于永刚;廖松柏;武英杰肾盂恒压灌注对肾损伤的实验研究[J].臨床泌尿外科雜誌.21卷5期(2006/05)387-389
[7]陈庆;黄峻;王敬良等;α和β受体阻滞剂对兔心肌病心肌代谢影响的研究,[J]南京医科大学学报,1988,04,000
[8]Andersson KE.Department of Clinical Pharmacology,Institute for Laboratory Medicine,Lund University Hospital,Sweden.Karl-Erik.Andersson@klinfarm.lu.se World J Urol.2002 Apr;19(6):390-6.
[9]Zhang Jing Ming,Wu Wei.Effects of Adrenergic Receptor Anagonist on Myocardial a 1-AR Density and Cardiac Electrophysiological Stability in Rabbits After Myocardial Infarction[J].JOURNAL OF SUN YAT-SEN UNIVERSITY(MEDICAL SCIENCES),2003 Vol.24 No.6 P.552-555
[10]谢协驹,吉丽敏,符史干.α受体阻滞剂对心肌细胞肥大的作用[J].海南医学,2001 Vol.12 No.1 P.57-58.
[11]Hampel C,Dolber PC,Salvic SL,et al.Changes in alphal adrenoceptor subtypes genen expression during bladder outlet obstruction of rats.J Urol,2000,163:228
[12]Yashiyama M,De WC,Role of spinal alphal-adrenoceptors subtypes in the bladder reflex in anesthetized rats.Am J Physiol Regul Intergr Comp Physiol 2001,280:1414-1419.
[13]Roehrbom CG:Alfuzosin:overview of pharmacokinetics,safety and efficacy of a clinically uroselective alpha-blocher.Urology,2001,58:55-63.
[14]Zhou Yuhai,Zhang Jing.The clinical report of the follow-up of radiofrequency thermotherapy and a lA adrenoceptor antagonist for the treatment of benign prostatic hyperplasia.[J]Journal of Taishan Medical College,2006,05-0443-03
[15]Aso Y,Homma Y.Clinical research criteria:response criteria for evaluating efficacy of treatments of benign prostatic hypertrophy.Br J Urol,1995,76(Suppl 1):69-73
[16]许文杰.前列腺增生症的药物治疗[J].广东药学,2000,Vol.10,No.5,P.10-11.
[17]朱卫国,局部给药联合α1-肾上腺素能受体阻滞剂治疗慢性非细菌性前列腺炎疗效观察[J].四川医学,2006,02-0169-02.
[18]Barbalias GA.Clinical and theraputical guidelines for chronic prostati-tis.EurUrol,2000,37(1):116-117
[19]陈文军,郑孝东;规律排精联合α1-肾上腺素能受体阻滞剂治疗非细菌性前列腺炎疗效观察[J]中华医学研究杂志 2003,3(3)3
[20]李昕,李宁忱,丁强,蔡松良.α1肾上腺素能受体阻滞剂萘哌地尔治疗慢性非细菌性前列腺炎的临床研究[J].中华男科学杂志2006 V01.12 No.3P.234-236,239
[21]陈晓松,叶章群,曾晓勇,坦索罗辛治疗非细菌性慢性前列腺炎临床分析[J].中华男科学,2002 Vol.8 No.1 P.51-53
[22]Barbalias GA.Clinical and theraputical guidelines for chronic prostatitis[J].Eur Urol,2000,37(1):116-117.
[23]叶章群,尿石症诊断治疗指南。那彦群主编,中国泌尿外科疾病诊断治疗指南。北京:人民卫生出版社。
[24]Kaplan SA.Serum human glandular kallikrein(hK2) and insulin-like growth factor(IGF-1) improve the discrimination between prostate cancer and bnign prostatic hyperplasia in combination with total and free PSA.J Urol.2003],170(1):343.
[25]Barbalias G A,Nikiforidis G;Liatsikos E N.Alphablockers for the treatment of chronic prostatitis in combination with antibiotics.J Urol,1998,159:883-887.
[26]Miehelle I W,Donna McTavish.Tamsulosin:A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia.Drugs,1996,52:883-898.
[27]邓春华,梁宏,梅骅,等.前列腺内尿液返流在慢性前列腺炎发病中的应用.中华泌尿外科杂志,1998,19(6):288-289.
[28]Lukacs B,Bloudin P,Mac Carthy C,et al.Safety Profile of 3Months'Therapy With Alfazosin 13389 Patients Suffring from Benign Prostatic Hypertrophy.Eur.Urol.1996,29:29-35
[29]Lepor H.The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia.J Urol,1991,12:389-394
[30]Lepor H,Jones K,Williford W,The mechanisms of adverse events associated with terazosin:an ananlysis study.J Urol,2000,163:1134-1137.
[31]Michel MC,Flannery MT,Narayan P,Worldwide experience with Alfuzosin and tamsulosin.Urology,2001,58:508-516.
[32]Yamamoto T,Ghost R,De WC,et al,Facilitation of transmitter release in the urinary bladder of neonatal and adult rats via alphal-adrenoceptors.Eur J Pharmocol,2001,414:31-35.
[33]Amobi N,Guillebaud J,Coker C,et al,Functional characterization of alphal adrenoceptor subtypes in longitudinal and circle muscle of human vas deferens.Eur J Pharmocol 1999,367:291-298.
[34]Taniguchi N,Ukai Y,Tanaka T,et al.Identification of alpha 1-adrenoceptor subtypes in human prostatic urethra.Naunyn Schmiedebergs Arch Pharmocol 1997,355:412-416.
[35]Kyprianou N,Litvak JP,Borkowski A,et al.Induction of prostate apoptosis by doxazosin in benign prostatic hyperplsia.J Urol 1998,159:1810-1815
[36]Walden PD,Gerardi C,Lepor H,et al.Localisation and expression of the alphalA-1,alphalB,alphalD-adrenoceptors in hyperplastic and non-hyperplatic human prastate.J Uro1,1999,161:635-640.
[37]Hayashi T,Sakai Y,Saito K,A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia.Hinyokika Kiyo 2002 Jan;48(1):7-11
[38]Mottet N,Bressolle F,Costa P,et al.Orally administered alfuzosin has a high prostatic hyperplasia.J Urol 2000,163:305.
[39]KRIEGER JN,RILEY DE,ROBERES MC,et al.Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis[J].J Clin Micro,1996,34:3120-3128.
[40]何乐业.前列腺炎综合征.中华泌尿外科杂志,2000,21:697-699.
[41]Wilson TA,Foxall TL,Nicolosi RJ,et al.Doxazosin,an alpha-1 antagonist prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters[J].Metabolism,2003,52(10):1240-1245
[42]Courtney CH,McCance DR,Atkinson AB,et al.Effect of the alpha-adrenergic blocker,doxazosin,on endothelial function and insulin action[J].Metabolism,2003,52(9):1147-1152
[43]Yavascaoglu I,Oktay,Simsek U,et al.Role of ejaculation in the treatment of chonic non-bacterial prostatitis.Int JUrol,1999,6:130-134.
[44]Rimoldi O,Spyrou N,Foale R,et al.Limitation of coronary reserve after successful angioplasty is prevented by oral pretreatment with an alphal-adrenergic antagonist[J].J Cardiovasc Pharmacol,2000,36(3):310-315
[45]杨君,赵仙先,秦永文,等.多沙唑嗪抑制大鼠血管平滑肌细胞增殖的实验研究[J].中国动脉硬化杂志,2002,10(3):234-235
[46]Jagroop IA,Mikhailidis DEDoxazosin,an alphal-adrenoceptor antagonist,inhibits serotonin-induced shape change in human platelets[J].J Hum Hyp ertens,2001,15(3):203-207
[47]Lepor H,Tang R,Shapiro E.The alpha-adrenoceptor subtype mediating tension of prostatic smooth muscle.Prostate 1993,22:301-307.
[48]Roehrborn CG.Alfuzosin:overview of pharmacokinetics,safety and efficacy of a clinically uroselective alpha-blocher.Urology,2001,58:55-63.
[50]Nickel JC.Prostatitis and related disorder[A]//Retik AB,Vaughan ED,W ein AJ,et al.Campbell's urology[M].8th ed.Philadelphia:Saunders,2002:603-630.
[51]Seljeflot I,Arnesen H,Andersen P,et al.Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men[J].J Cardiovasc Pharmacol,1999,34(4):584-588
[52]Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.Diuretic versus alpha-blocker as first-step antihypertensive therapy:final results from the antihypertensive and lipid-Lowering treatment to prevent heart attack Trial(ALLHAT)[J].Hypertension,2003,42(3):2392-46
[52]Wilde MI,Fitton A,Mc Tavish D.Alfuzosin:a review of its pharmacodynamic and pharmacokinetic properties,and therapeatic potential in benign prostatic hyperplas.Drugs,1993,45(3):410-429
[53]Kyprianou N.TUHC.Jacobs SC Apoptotic versus proliferatic activities in human BPH 19960
[54]Chon J,Borkowski A,Partin A W,et al.al adrenoceptor antagonist terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patient with benign prostatic hyperplasia[J].J Urol,1999,161(6):2002 2007
[55]Porpiglia F,Ghignone G,Fiori C,et al.Nifedipine versus tamsulosin for the management of lower ureteral stones.J Urol,2004,172(2):568-571.
[56]Bajor G.Beta-blocking agent facilitating the spontaneous passage of ureteral stones.Int Urol Nephrol,1990,22(1):33-36.
[57]Borghi L,Meschi T,Amato F,et al.Nifedipine and methylprednisolone in facilitating ureteral stone passage:a randomized,doubleblind,placebo-controlled study.JUrol,1994,152(4):1095-1098.
[58]Morita T,Ando M,Kihara K,et al.Function and distribution of autonomic receptors in canine ureteral smooth muscle.Neurourol Urodyn,1994,13(3):315-321.
[59]李强,卓晖,袁仁斌,选择性α受体阻滞剂在输尿管结石治疗中的应用[J]中华临床医师杂志2008 2(2)2
[60]熊玮,王坤杰,王莉,等.坦索罗辛用于输尿管结石排石治疗随机对照试验的Me ta分析.中国循证医学杂志,2007,7(7):506-513.
[61]Desio M,Autorino R,Dilorenzo G,et al.Medical expulsive treatment of distal-ureteral stones using tamsulosin[J]:a single-center experience.J Endourol,2006,20;12-16.
[62]吕家驹 尉立京 张辉,等,坦索罗辛和硝苯地平在输尿管下段结石辅助排石中作用的比较[J],中华泌尿外科杂志2006,9;612.614
[63]夏祥阶,刘海涛,琥珀消石冲剂联合哈乐治疗输尿管下段结石疗效观察[J],齐鲁护理杂志 2006,8;1602.
[64]Muramatsu I,Taniguchi T,Okada K,Tamsulosin:alphal adrenoceptors subtype-selectivity and comparison with the terazosin.Jpn J pharmacol 1998,78:331-335.
[65]Richard G;Batstone D,Doble A.Chronic prostatitis.Curr Opin Urol,2003,13:23-29.
[2]Cooper JT,stack GM.Intensive Medical management of ureteral calculi.Urology,2000,56(4):575-578
[3]Sigala S,Dellabella M,Milanese G;et al.Evidence for the presence of alphal adrenoceptor subtypes in the human ureter.Neurourol Urodyn,2005,24(2):142-148.
[4]孙西钊,叶章群.。肾绞痛诊断和治疗新概念.临床泌尿外科杂志,2007,10(5):321-323.
[5]Borghi L,Meschi T,Amato F,et al.Nifedipine and methylprednisolone in facilitating ureteral stone passage:a randomized,doubleblind,placebo-controlled study.J Urol,1994,152(4):1095--1098.
[6]Parsons JK,Hergan LA,Sakamoto K,et al.Efficacy of alpha-Blockers for the Treatment ofUreteral Stones.J Urol,2007,177(3):983--987.
[7]李涛,何延瑜,陈圣,等.特拉唑嗪联合硝苯地平治疗输尿管末端结石的随机对照临床研究.中华泌尿外科杂志,2007,28(2):111-114.
[8]叶章群,尿石症诊断治疗指南。那彦群主编,中国泌尿外科疾病诊断治疗指南。北京:人民卫生出版社。
[9]Cervenakov I,Fillo J,Mardiak J,et al.Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker-Tamsulosin.Int Urol Nephrol,2002,34(1):25-29.
[10]王风,曹清丽,张瑜,等.盐酸坦索罗辛治疗输尿管远段小结石的临床研究.中国医师进修杂志:外科版,2006,29(10):52-53.
[11]Rocco D.Riccardo A.Ciro E Stent positioning after ureteroscopy for urinary calcail:The question is still open 2004(3)
[12]刘福泉 童高寅α受体阻滞剂在输尿管下段结石临床应用,浙江临床医学2008,10(10)9
[13]Gravina GI.Costa AM.Ronchi P Tamsulosin treatment increases clinical success rate of single extra corporeal shock wave lithotripsy of renal stones 20050
[14]Resim S.Ekerbicer H K.Cifit A Role of Tamsulosin in treatment of patients with steinstrasse developing after extracorporeal shock wave lithotripsy 2005(5)
[15]丁森泰,吕家驹,叶章群.Cc受体阻滞剂在输尿管下段结石治疗中的研究.临床泌尿外科杂志,2007,22(5):394-396.
[16]Dellabella M,Milanese G,Muzzonigre GRandomized trial of the efficacy of tamsulosin,nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi.J Urol,2005,174(1):167--172.
[17]2007Teichman JM.Clinical practice.Acute renal colic from ureteral calculus.NEngl J Med,2004,350(7):684--693.
[1]Akasaka T,Funaki H,Hirano S,Ohinata M,Fujishima M,Kudou T,Suzuki A,Iinuma M.Department of Urology,Akasaka Hospital..Hinyokika Kiyo.2003Apr;49(4):189-93.
[2]汤平,谢克基,α1-肾上腺素能受体阻滞剂与前列腺细胞凋亡[J].广东医学L,2002 Vo1.23 No.7 P.765-767
[3]Kyprianou N.Division of Urology,Department of Surgery,University of Kentucky Medical Center,Lexington,USA.J Urol.2003 Apr;169(4):1520-5.
[4].Wilt T J,Mac Donald R,Rutks I.General Internal Medicine(111-0),Minneapolis VA/VISN 23 Center for Chronic Disease Outcomes Research,One Veterans Drive,Minneapolis,Minnesota 55417,USA.Tim.Wilt@rned.va.gov Cochrane Database Syst Rev.2003;(1):CD002081
[5]Thiyagarajan M.Department of Pharmacology and Toxicology,National Institute of Pharmaceutical Education and Research,SAS Nagar(Mohali),India.m-t-rajan@hotmail.com Pharmacology.2002 Jul;65(3):119-28.
[6]于永刚;廖松柏;武英杰肾盂恒压灌注对肾损伤的实验研究[J].臨床泌尿外科雜誌.21卷5期(2006/05)387-389
[7]陈庆;黄峻;王敬良等;α和β受体阻滞剂对兔心肌病心肌代谢影响的研究,[J]南京医科大学学报,1988,04,000
[8]Andersson KE.Department of Clinical Pharmacology,Institute for Laboratory Medicine,Lund University Hospital,Sweden.Karl-Erik.Andersson@klinfarm.lu.se World J Urol.2002 Apr;19(6):390-6.
[9]Zhang Jing Ming,Wu Wei.Effects of Adrenergic Receptor Anagonist on Myocardial a 1-AR Density and Cardiac Electrophysiological Stability in Rabbits After Myocardial Infarction[J].JOURNAL OF SUN YAT-SEN UNIVERSITY(MEDICAL SCIENCES),2003 Vol.24 No.6 P.552-555
[10]谢协驹,吉丽敏,符史干.α受体阻滞剂对心肌细胞肥大的作用[J].海南医学,2001 Vol.12 No.1 P.57-58.
[11]Hampel C,Dolber PC,Salvic SL,et al.Changes in alphal adrenoceptor subtypes genen expression during bladder outlet obstruction of rats.J Urol,2000,163:228
[12]Yashiyama M,De WC,Role of spinal alphal-adrenoceptors subtypes in the bladder reflex in anesthetized rats.Am J Physiol Regul Intergr Comp Physiol 2001,280:1414-1419.
[13]Roehrbom CG:Alfuzosin:overview of pharmacokinetics,safety and efficacy of a clinically uroselective alpha-blocher.Urology,2001,58:55-63.
[14]Zhou Yuhai,Zhang Jing.The clinical report of the follow-up of radiofrequency thermotherapy and a lA adrenoceptor antagonist for the treatment of benign prostatic hyperplasia.[J]Journal of Taishan Medical College,2006,05-0443-03
[15]Aso Y,Homma Y.Clinical research criteria:response criteria for evaluating efficacy of treatments of benign prostatic hypertrophy.Br J Urol,1995,76(Suppl 1):69-73
[16]许文杰.前列腺增生症的药物治疗[J].广东药学,2000,Vol.10,No.5,P.10-11.
[17]朱卫国,局部给药联合α1-肾上腺素能受体阻滞剂治疗慢性非细菌性前列腺炎疗效观察[J].四川医学,2006,02-0169-02.
[18]Barbalias GA.Clinical and theraputical guidelines for chronic prostati-tis.EurUrol,2000,37(1):116-117
[19]陈文军,郑孝东;规律排精联合α1-肾上腺素能受体阻滞剂治疗非细菌性前列腺炎疗效观察[J]中华医学研究杂志 2003,3(3)3
[20]李昕,李宁忱,丁强,蔡松良.α1肾上腺素能受体阻滞剂萘哌地尔治疗慢性非细菌性前列腺炎的临床研究[J].中华男科学杂志2006 V01.12 No.3P.234-236,239
[21]陈晓松,叶章群,曾晓勇,坦索罗辛治疗非细菌性慢性前列腺炎临床分析[J].中华男科学,2002 Vol.8 No.1 P.51-53
[22]Barbalias GA.Clinical and theraputical guidelines for chronic prostatitis[J].Eur Urol,2000,37(1):116-117.
[23]叶章群,尿石症诊断治疗指南。那彦群主编,中国泌尿外科疾病诊断治疗指南。北京:人民卫生出版社。
[24]Kaplan SA.Serum human glandular kallikrein(hK2) and insulin-like growth factor(IGF-1) improve the discrimination between prostate cancer and bnign prostatic hyperplasia in combination with total and free PSA.J Urol.2003],170(1):343.
[25]Barbalias G A,Nikiforidis G;Liatsikos E N.Alphablockers for the treatment of chronic prostatitis in combination with antibiotics.J Urol,1998,159:883-887.
[26]Miehelle I W,Donna McTavish.Tamsulosin:A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia.Drugs,1996,52:883-898.
[27]邓春华,梁宏,梅骅,等.前列腺内尿液返流在慢性前列腺炎发病中的应用.中华泌尿外科杂志,1998,19(6):288-289.
[28]Lukacs B,Bloudin P,Mac Carthy C,et al.Safety Profile of 3Months'Therapy With Alfazosin 13389 Patients Suffring from Benign Prostatic Hypertrophy.Eur.Urol.1996,29:29-35
[29]Lepor H.The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia.J Urol,1991,12:389-394
[30]Lepor H,Jones K,Williford W,The mechanisms of adverse events associated with terazosin:an ananlysis study.J Urol,2000,163:1134-1137.
[31]Michel MC,Flannery MT,Narayan P,Worldwide experience with Alfuzosin and tamsulosin.Urology,2001,58:508-516.
[32]Yamamoto T,Ghost R,De WC,et al,Facilitation of transmitter release in the urinary bladder of neonatal and adult rats via alphal-adrenoceptors.Eur J Pharmocol,2001,414:31-35.
[33]Amobi N,Guillebaud J,Coker C,et al,Functional characterization of alphal adrenoceptor subtypes in longitudinal and circle muscle of human vas deferens.Eur J Pharmocol 1999,367:291-298.
[34]Taniguchi N,Ukai Y,Tanaka T,et al.Identification of alpha 1-adrenoceptor subtypes in human prostatic urethra.Naunyn Schmiedebergs Arch Pharmocol 1997,355:412-416.
[35]Kyprianou N,Litvak JP,Borkowski A,et al.Induction of prostate apoptosis by doxazosin in benign prostatic hyperplsia.J Urol 1998,159:1810-1815
[36]Walden PD,Gerardi C,Lepor H,et al.Localisation and expression of the alphalA-1,alphalB,alphalD-adrenoceptors in hyperplastic and non-hyperplatic human prastate.J Uro1,1999,161:635-640.
[37]Hayashi T,Sakai Y,Saito K,A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia.Hinyokika Kiyo 2002 Jan;48(1):7-11
[38]Mottet N,Bressolle F,Costa P,et al.Orally administered alfuzosin has a high prostatic hyperplasia.J Urol 2000,163:305.
[39]KRIEGER JN,RILEY DE,ROBERES MC,et al.Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis[J].J Clin Micro,1996,34:3120-3128.
[40]何乐业.前列腺炎综合征.中华泌尿外科杂志,2000,21:697-699.
[41]Wilson TA,Foxall TL,Nicolosi RJ,et al.Doxazosin,an alpha-1 antagonist prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters[J].Metabolism,2003,52(10):1240-1245
[42]Courtney CH,McCance DR,Atkinson AB,et al.Effect of the alpha-adrenergic blocker,doxazosin,on endothelial function and insulin action[J].Metabolism,2003,52(9):1147-1152
[43]Yavascaoglu I,Oktay,Simsek U,et al.Role of ejaculation in the treatment of chonic non-bacterial prostatitis.Int JUrol,1999,6:130-134.
[44]Rimoldi O,Spyrou N,Foale R,et al.Limitation of coronary reserve after successful angioplasty is prevented by oral pretreatment with an alphal-adrenergic antagonist[J].J Cardiovasc Pharmacol,2000,36(3):310-315
[45]杨君,赵仙先,秦永文,等.多沙唑嗪抑制大鼠血管平滑肌细胞增殖的实验研究[J].中国动脉硬化杂志,2002,10(3):234-235
[46]Jagroop IA,Mikhailidis DEDoxazosin,an alphal-adrenoceptor antagonist,inhibits serotonin-induced shape change in human platelets[J].J Hum Hyp ertens,2001,15(3):203-207
[47]Lepor H,Tang R,Shapiro E.The alpha-adrenoceptor subtype mediating tension of prostatic smooth muscle.Prostate 1993,22:301-307.
[48]Roehrborn CG.Alfuzosin:overview of pharmacokinetics,safety and efficacy of a clinically uroselective alpha-blocher.Urology,2001,58:55-63.
[50]Nickel JC.Prostatitis and related disorder[A]//Retik AB,Vaughan ED,W ein AJ,et al.Campbell's urology[M].8th ed.Philadelphia:Saunders,2002:603-630.
[51]Seljeflot I,Arnesen H,Andersen P,et al.Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men[J].J Cardiovasc Pharmacol,1999,34(4):584-588
[52]Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.Diuretic versus alpha-blocker as first-step antihypertensive therapy:final results from the antihypertensive and lipid-Lowering treatment to prevent heart attack Trial(ALLHAT)[J].Hypertension,2003,42(3):2392-46
[52]Wilde MI,Fitton A,Mc Tavish D.Alfuzosin:a review of its pharmacodynamic and pharmacokinetic properties,and therapeatic potential in benign prostatic hyperplas.Drugs,1993,45(3):410-429
[53]Kyprianou N.TUHC.Jacobs SC Apoptotic versus proliferatic activities in human BPH 19960
[54]Chon J,Borkowski A,Partin A W,et al.al adrenoceptor antagonist terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patient with benign prostatic hyperplasia[J].J Urol,1999,161(6):2002 2007
[55]Porpiglia F,Ghignone G,Fiori C,et al.Nifedipine versus tamsulosin for the management of lower ureteral stones.J Urol,2004,172(2):568-571.
[56]Bajor G.Beta-blocking agent facilitating the spontaneous passage of ureteral stones.Int Urol Nephrol,1990,22(1):33-36.
[57]Borghi L,Meschi T,Amato F,et al.Nifedipine and methylprednisolone in facilitating ureteral stone passage:a randomized,doubleblind,placebo-controlled study.JUrol,1994,152(4):1095-1098.
[58]Morita T,Ando M,Kihara K,et al.Function and distribution of autonomic receptors in canine ureteral smooth muscle.Neurourol Urodyn,1994,13(3):315-321.
[59]李强,卓晖,袁仁斌,选择性α受体阻滞剂在输尿管结石治疗中的应用[J]中华临床医师杂志2008 2(2)2
[60]熊玮,王坤杰,王莉,等.坦索罗辛用于输尿管结石排石治疗随机对照试验的Me ta分析.中国循证医学杂志,2007,7(7):506-513.
[61]Desio M,Autorino R,Dilorenzo G,et al.Medical expulsive treatment of distal-ureteral stones using tamsulosin[J]:a single-center experience.J Endourol,2006,20;12-16.
[62]吕家驹 尉立京 张辉,等,坦索罗辛和硝苯地平在输尿管下段结石辅助排石中作用的比较[J],中华泌尿外科杂志2006,9;612.614
[63]夏祥阶,刘海涛,琥珀消石冲剂联合哈乐治疗输尿管下段结石疗效观察[J],齐鲁护理杂志 2006,8;1602.
[64]Muramatsu I,Taniguchi T,Okada K,Tamsulosin:alphal adrenoceptors subtype-selectivity and comparison with the terazosin.Jpn J pharmacol 1998,78:331-335.
[65]Richard G;Batstone D,Doble A.Chronic prostatitis.Curr Opin Urol,2003,13:23-29.